


Total Synthesis of Aplyronine A, a Potent Antitumor Substance of Marine Origin

Hideo Kigoshi, Makoto Ojika, Takeshi Ishigaki, Kiyotake Suenaga, Tsuyoshi Mutou, Akira Sakakura, Takeshi Ogawa, and Kiyoyuki Yamada*

Department of Chemistry, Faculty of Science
Nagoya University, Chikusa, Nagoya 464, Japan

Received March 17, 1994

Recently, we elucidated the gross structure of aplyronine A (1) isolated as a minute constituent of the Japanese sea hare *Aplysia kurodai*.^{1a} Further, the absolute stereochemistry of 1 has been fully determined.^{1b–d} Although aplyronine A (1) exhibits




exceedingly potent antitumor activities,^{1a} the scarcity of 1 from natural sources has prevented further evaluation of this compound as a potential therapeutic agent thus far. This fact and the novel polyfunctional 24-membered lactone structure prompted us to initiate the investigation toward the synthesis of 1. Recently, the synthesis of the C21–C34 segment² of 1 has been reported.³ We describe herein the total synthesis of 1.

Scheme 1 outlines the synthesis of aplyronine A (1), which includes the following key operations: (1) the four contiguous asymmetric centers C7–C10 of the C5–C11 segment 2 were constructed by the Evans aldol reaction⁴ and the Sharpless epoxidation;⁵ (2) the C5–C20 segment 5 was synthesized by connecting the three segments 2, 3, and 4 in order; and (3) a Julia olefination reaction⁶ between the C5–C20 segment 5 and the C21–C34 segment 6.³


The synthesis of the C5–C11 segment 2 began with the Evans aldol reaction between imide 7⁴ and (*R*)-3-(benzyloxy)-2-methylpropanal⁷ (Scheme 2), which led to amide 8⁸ by two steps. Conversion of 8 into allyl alcohol 9 was effected by a three-step sequence including the Horner–Emmons reaction. The Sharpless epoxidation⁵ of 9 followed by regioselective reduction with Red-Al⁹ provided diol 10, which was transformed into 2 (53% overall yield from imide 7) by a five-step sequence.

The alkylation reaction¹⁰ of 2 with iodide 3¹¹ and subsequent reductive removal of the sulfonyl group afforded benzyl ether 11,

Scheme 1



Scheme 2^a



^a (a) Bu₂BOTf, Et₃N, CH₂Cl₂, 0 °C, then (*R*)-3-(benzyloxy)-2-methylpropanal, –78 → 0 °C. (b) Me₂AlN(Me)OMe, THF, toluene, –10 → 0 °C. (c) *t*-BuMe₂SiOTf (TBSOTf), 2,6-lutidine, CH₂Cl₂, 0 °C. (d) DIBAL, THF, hexane, –78 °C. (e) (*i*-PrO)₂P(O)CH₂COOEt, *t*-BuOK, THF, –78 → 0 °C. (f) DIBAL, hexane, CH₂Cl₂, –78 °C. (g) Ti(OPr-*i*)₄, (+)-diethyl tartrate, *t*-BuOOH, molecular sieves 4 Å, CH₂Cl₂, –23 °C. (h) Red-Al, DME, 0 °C. (i) Pivaloyl chloride (PivCl), pyridine, 0 °C. (j) H₂, 10% Pd–C, EtOH. (k) (PhS)₂, Bu₃P, DMF. (l) Et₃SiCl (TESCl), imidazole, DMF. (m) *m*-CPBA, NaHCO₃, CH₂Cl₂.

which was converted into methyl ketone 12 in four steps (Scheme 3). The Julia coupling⁶ between 12 and the C15–C20 segment 4¹³ provided *trans*-olefin 13,¹⁵ which was transformed into the C5–C20 segment 5 (17% overall yield from 2) in four steps.

The Julia coupling between the C5–C20 segment 5 and the C21–C34 segment 6¹⁶ gave an olefin¹⁸ (Scheme 4), which was converted into *seco*-acid 14¹⁹ by a five-step sequence involving the Horner–Emmons reaction.²⁰ The macrolactonization of 14

(1) (a) Yamada, K.; Ojika, M.; Ishigaki, T.; Yoshida, Y.; Ekimoto, H.; Arakawa, M. *J. Am. Chem. Soc.* **1993**, *115*, 11020–11021. (b) Ojika, M.; Kigoshi, H.; Ishigaki, T.; Yamada, K. *Tetrahedron Lett.* **1993**, *34*, 8501–8504. (c) Ojika, M.; Kigoshi, H.; Ishigaki, T.; Nisiwaki, M.; Tsukada, I.; Mizuta, K.; Yamada, K. *Tetrahedron Lett.* **1993**, *34*, 8505–8508. (d) Ojika, M.; Kigoshi, H.; Ishigaki, T.; Tsukada, I.; Tsuboi, T.; Ogawa, T.; Yamada, K. *J. Am. Chem. Soc.*, preceding paper in this issue.

(2) The numbering used in this paper corresponds to that of 1.

(3) Kigoshi, H.; Ojika, M.; Suenaga, K.; Mutou, T.; Hirano, J.; Sakakura, A.; Ogawa, T.; Nisiwaki, M.; Yamada, K. *Tetrahedron Lett.* **1994**, *35*, 1247–1250.

(4) Evans, D. A.; Bartolli, J.; Shih, T. L. *J. Am. Chem. Soc.* **1981**, *103*, 2127–2129.

(5) Katsuki, T.; Sharpless, K. B. *J. Am. Chem. Soc.* **1980**, *102*, 5974–5976.

(6) Julia, M.; Paris, J.-M. *Tetrahedron Lett.* **1973**, 4833–4836.

(7) Meyers, A. I.; Babiak, K. A.; Campbell, A. L.; Comins, D. L.; Fleming, M. P.; Henning, R.; Heuschmann, M.; Hudspeth, J. P.; Kane, J. M.; Reider, P. J.; Roland, D. M.; Shimizu, K.; Tomioka, K.; Walkup, R. D. *J. Am. Chem. Soc.* **1983**, *105*, 5015–5024.

(8) Satisfactory spectroscopic data (IR, ¹H NMR, MS, and HRMS) were obtained for all new compounds.

(9) Finan, J. M.; Kishi, Y. *Tetrahedron Lett.* **1982**, *23*, 2719–2722. Nicolaou, K. C.; Uenishi, J. *J. Chem. Soc., Chem. Commun.* **1982**, 1292–1293.

(10) Kondo, K.; Tunemoto, D. *Tetrahedron Lett.* **1975**, 1007–1010.

(11) The iodide 3 was prepared in 81% overall yield from commercially available (*R*)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol in seven steps [(1) BnBr, NaH; (2) HCl, aqueous acetone; (3) TBSCl, DMAP, Et₃N; (4) MeI, NaH; (5) Bu₄NF; (6) TsCl, pyridine; (7) NaI].

(12) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155–4156.

(13) The C15–C20 segment 4 was prepared in 31% overall yield from commercially available (*R*)-(-)-dihydro-5-(hydroxymethyl)-2(3*H*)-furanone [(1) TrCl, pyridine; (2) MeI, LDA; (3) LiAlH₄; (4) TBDPSCl, imidazole; (5) MeI, NaH; (6) Bu₄NF; (7) TsCl, pyridine; (8) PhSO₂Me, BuLi].

(14) Tomioka, K.; Cho, Y.-S.; Sato, F.; Koga, K. *J. Org. Chem.* **1988**, *53*, 4094–4098.


(15) The *cis*-olefin (20%) and the C14-tertiary alcohol (23%) were obtained along with *trans*-olefin 13 (44%).

(16) The C21–C34 segment 6 was synthesized by protection of the C29 hydroxyl group of the corresponding alcohol³ as its (3,4-dimethoxyphenyl)-methoxymethyl ether ((3,4-dimethoxyphenyl)methoxymethyl chloride,¹⁷ *i*-Pr₂NEt, CH₂Cl₂, 98%).

(17) Gündel, W.-H.; Kramer, W. *Chem. Ber.* **1978**, *111*, 2594–2604. Kozikowski, A. P.; Wu, J.-P. *Tetrahedron Lett.* **1987**, *28*, 5125–5128.

(18) The *trans*/*cis* ratio of the olefin was ca. 10:1. The minor isomer could be separated by HPLC after macrolactonization.

(19) The *trans*/*cis* ratio at the C4 double bond was ca. 20:1. The minor isomer could be separated by HPLC after macrolactonization.

Scheme 3^a

^a (a) 2, LDA, THF, -78°C , then 3, HMPA. (b) 5% Na-Hg, Na_2HPO_4 , MeOH, 0°C . (c) H_2 , 10% Pd-C, NaHCO_3 , EtOH. (d) Dess-Martin reagent,¹² pyridine, CH_2Cl_2 . (e) Me_2CuLi , ether, -78°C . (f) Dess-Martin reagent,¹² pyridine, CH_2Cl_2 . (g) 4, BuLi, THF, -78°C . (h) 6% Na-Hg, Na_2HPO_4 , MeOH, 0°C . (i) AcOH, H_2O , THF. (j) DMSO, Ac_2O , AcOH, $23 \rightarrow 40^{\circ}\text{C}$. (k) HCOOH, ether. (l) Dess-Martin reagent,¹² pyridine, CH_2Cl_2 .

was accomplished by the Yamaguchi method²¹ to yield the 24-membered lactone 15 (42%) and a 26-membered lactone (28%).²² After silylation of the hydroxyl group of 15, the methyl acetal moiety was hydrolyzed to afford a hemiacetal, which was reduced to give diol 16. Diol 16 was converted into aldehyde 17 by a four-step sequence. The terminal *N*-methyl-*N*-vinylformamide structure was constructed by reaction of 17 with *N*-methylformamide to afford enamide 18. Removal of the protecting group at C29 in 18 was accomplished by DDQ,²³ and the resulting hydroxyl group was acylated with *N,N*-dimethylalanine (*S*:*R* = 3:2²⁴) under Keck conditions²⁵ to give a diastereomeric mixture of dimethylalanine esters (*S*:*R* = 4:1).²⁶ Further, hydrolysis of the (methylthio)methyl (MTM) group at C7 with AgNO_3 ²⁷ and acylation of the hydroxyl group with *N,N,O*-trimethylserine (*S*:*R* = 5:2²⁸) gave a diastereomeric mixture of trimethylserine esters (*S*:*R* = 4:3),²⁶ the two silyl groups of which were removed to provide aplyronine A (1). Synthetic aplyronine A (1) was found to correspond uniquely to natural 1 by comparison of the spectroscopic (UV, IR, ^1H NMR, MS, α_D) and chromatographic properties and cytotoxicity.²⁹

Acknowledgment. This work was supported in part by Grants-in-Aid for Scientific Research (Nos. 04403009 and 03640472)

(20) Sato, K.; Mizuno, S.; Hirayama, M. *J. Org. Chem.* 1967, 32, 177-180.

(21) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* 1979, 52, 1989-1993. Hikota, M.; Sakurai, Y.; Horita, K.; Yonemitsu, O. *Tetrahedron Lett.* 1990, 31, 6367-6370.

(22) The 26-membered lactone could be isomerized to the 24-membered lactone 15 under the equilibrium conditions (15/26-membered lactone = ca. 2.5:1) in the presence of $\text{Ti}(\text{O}i\text{-Pr})_4$ (15, 60-65% isolation yield).

(23) Under a variety of conditions for the deprotection of the corresponding (*p*-methoxyphenyl)methoxymethyl ether protecting group at C29 with DDQ, the conjugated lactone group was oxidatively decomposed.


(24) Esterification of the C29 hydroxyl group with (*S*)-*N,N*-dimethylalanine gave a >9:1 mixture of the (2'*S*)- and (2'*R*)-dimethylalanine esters, whereas that with (*R*)-*N,N*-dimethylalanine afforded a 1:1 mixture of the esters.

(25) Boden, E. P.; Keck, G. E. *J. Org. Chem.* 1985, 50, 2394-2395.

(26) Natural aplyronine A (1) was obtained as a diastereomeric mixture with respect to two amino acids.^{1a} The ratios varied with the animal samples employed, although the compounds with *S* configuration were always predominant (2-1.1:1 and 6-3:1 ratios for *N,N,O*-trimethylserine and *N,N*-dimethylalanine moieties, respectively).

(27) Corey, E. J.; Bock, M. G. *Tetrahedron Lett.* 1975, 3269-3270.

(28) Esterification of the C7 hydroxyl group with (*S*)-*N,N,O*-trimethylserine gave a 3:2 mixture of (2'*S*)- and (2'*R*)-trimethylserine esters, whereas that with (*R*)-*N,N,O*-trimethylserine afforded a 1:3 mixture of the esters.

Scheme 4^a

^a (a) 6, BuLi, THF, -78°C , then 5. (b) Ac_2O , DMAP, pyridine. (c) 5% Na-Hg, Na_2HPO_4 , MeOH, 0°C . (d) DIBAL, hexane, CH_2Cl_2 , -78°C . (e) Dess-Martin reagent,¹² pyridine, CH_2Cl_2 . (f) $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CH}=\text{CHCOOEt}$, LDA, THF, $-40 \rightarrow 0^{\circ}\text{C}$. (g) HF-pyridine, pyridine, THF. (h) LiOH, MeOH, H_2O . (i) $\text{C}_6\text{H}_5\text{Cl}_3\text{COCl}$, DMAP, Et_3N , CHCl_3 . (j) *t*-BuMe₂SiCl (TBSCl), imidazole, DMF, 60°C . (k) HCl, H_2O , DME. (l) $\text{NaBH}(\text{OMe})_3$, MeOH. (m) TrCl, pyridine, 50°C . (n) Ac_2O , DMAP, pyridine. (o) HCOOH, ether. (p) Dess-Martin reagent,¹² pyridine, CH_2Cl_2 . (q) MeNHCHO, PPTS, hydroquinone, benzene, reflux. (r) DDQ, phosphate buffer (pH 6), *t*-BuOH, CH_2Cl_2 . (s) *N,N*-Dimethylalanine (*S*:*R* = 3:2), DCC, DMAP, CSA, CH_2Cl_2 . (t) AgNO_3 , 2,6-lutidine, H_2O , THF. (u) *N,N,O*-trimethylserine (*S*:*R* = 5:2), DCC, DMAP, CSA, CH_2Cl_2 , 35°C . (v) HF-pyridine, pyridine.

and for Scientific Research on Priority Areas (Asymmetric Synthesis of Chiral Molecules) from the Ministry of Education, Science, and Culture, Japan, the Fujisawa Foundation, the Shorai Foundation for Science and Technology, the Kowa Life Science Foundation, the Naito Foundation, and Ono Pharmaceutical Co. T.I. gratefully acknowledges JSPS for a predoctoral fellowship.

Supplementary Material Available: Spectral data of intermediates and synthetic 1; ^1H NMR spectra of the pentaacetate^{1b} obtained from both natural and synthetic 1; ^1H and ^{13}C NMR spectra and HPLC traces of natural and synthetic 1 (29 pages). This material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

(29) The very small differences in the signal intensity of the ^1H and ^{13}C NMR spectra which were observed between natural and synthetic aplyronine A (1) are due to the different diastereomeric ratios of two amino acids. Synthetic 1 was subjected to the same sequence of degradations that was previously employed with natural 1 for removal of the two amino acids^{1b} to give the pentaacetate ($[\alpha]_D^{25} -14^{\circ}$ (*c* 0.06, CHCl_3)), corresponding to the carbon backbone of 1. The pentaacetate thus obtained was identical with that from natural 1 ($[\alpha]_D^{25} -15^{\circ}$ (*c* 0.16, CHCl_3))^{1b} in all respects.